Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT00398905 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

726

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Enoxaparin

Sponsor

Bayer